8. Goodwill and Intangible Assets, Net

Goodwill

There were no goodwill impairments recognized during the three and six months ended June 30, 2026 and 2025. The carrying value of goodwill, all of which is assigned to the Company’s BioBanking reporting unit, was $7,347 at both June 30, 2026 and December 31, 2025.

Intangible Assets, net

Intangible assets, net consisted of the following:

 Schedule of Intangible Assets, Net

Amortization expense for intangible assets was $354 and $372 for the three months ended June 30, 2026 and 2025, respectively. Amortization expense for intangible assets was $722 and $740 for the six months ended June 30, 2026 and 2025, respectively.

During the second quarter of 2026, the Company derecognized $0.7 million in acquired IPR&D product rights intangible assets upon reaching its settlement with Sequence. Under this settlement, the Company granted Sequence a fully paid, royalty-free, irrevocable, perpetual, transferrable, worldwide sublicense with respect to all of the assets properties, contractual rights, goodwill, going concern value, rights and claims licensed to or otherwise controlled by the Company related to Rebound Matrix Placental-Derived Allograft. Refer to Note 13 – Commitments and Contingencies for additional information.

No impairment charges were recorded on intangible assets for the three and six months ended June 30, 2025.

Aggregate amortization expense for each of the five succeeding years and thereafter related to intangible assets held as of June 30, 2026 is estimated as follows:

 Schedule of Aggregate Amortization Expense Related To Intangible Assets